Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow-up study of JVC-001 Phase III subjects for mumps, measles and rubella immunity
jRCTs031230590Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of measles, mumps and rubella vaccine (live) in measles, rubella and mumps (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Incidence of measles, rubella, and mumps and Antibody titers against measles virus, rubella virus, and mumps virus. Started Feb 2024; status: completed.
02
Drugs
measles, mumps and rubella vaccine (live)
03
Conditions
measlesrubellamumps
Beyond the preview
Go deeper on jRCTs031230590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230590.